Practical Management of Bispecific Antibodies in Multiple Myeloma.

Authors

Carlyn Rose Tan, Neha Korde, Hira Mian

Published in

JCO oncology practice. Pages OP2600159. Jun 17, 2026. Epub Jun 17, 2026.

Abstract

The treatment landscape for relapsed/refractory multiple myeloma has been transformed by the approval of T-cell-redirecting bispecific antibodies (BsAbs) targeting B-cell maturation antigen (teclistamab, elranatamab, and linvoseltamab) and GPRC5D (talquetamab). Although pivotal trials have demonstrated deep and durable responses, the rapid transition of these off-the-shelf agents from controlled clinical settings to routine oncologic practice presents significant operational and clinical challenges. This review focuses on the practical framework required to deliver BsAb therapy safely and effectively across academic and community settings. We address critical components of patient selection and effective implementation strategies, including infrastructure for the management of unique short-term toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, and long-term infection risks. We discuss models for outpatient implementation of these agents including the use of technology and academic-community partnerships (shared care models). As BsAbs move into earlier lines of therapy and combination regimens, optimizing these practical management strategies is essential to ensuring equitable access and maximizing long-term outcomes for patients with multiple myeloma.

PMID:
42308434
Bibliographic data and abstract were imported from PubMed on 18 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.